Franklin Strategic Series · net assets $1.04B · 113 holdings as of April 30, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 93.3% · STIV: 5.8% · EP: 0.5% · OTHER: 0.4%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $8.6M | $7.98M | $9.99M |
| Reinvestment | $59.4 | $0 | $0 |
| Redemptions | $22.4M | $15.9M | $15M |
| Net realized gain (non-derivative) | $11.9M | $15.9M | $43.6M |
| Net unrealized appreciation (non-derivative) | $20.7M | $-26.6M | $-20.5M |
The three months of the reporting period, as filed; month 3 ends April 30, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Jazz Pharmaceuticals PLC EC | $57.5M | 5.55% |
| Amgen, Inc. EC | $49.2M | 4.75% |
| Gilead Sciences, Inc. EC | $48.3M | 4.66% |
| Regeneron Pharmaceuticals, Inc. EC | $43.1M | 4.16% |
| Vertex Pharmaceuticals, Inc. EC | $41.6M | 4.02% |
| Argenx Se EC | $38.3M | 3.69% |
| Franklin Institutional U.s. Government Money Market Fund STIV | $31.6M | 3.05% |
| Franklin Institutional U.s. Government Money Market Fund STIV | $30.7M | 2.96% |
| Ascendis Pharma A/s EC | $29.8M | 2.87% |
| Insmed, Inc. EC | $29.2M | 2.82% |
| Revolution Medicines, Inc. EC | $29.2M | 2.82% |
| Praxis Precision Medicines, Inc. EC | $26M | 2.51% |
| Dianthus Therapeutics, Inc. EC | $23.8M | 2.30% |
| Guardant Health, Inc. EC | $21.7M | 2.09% |
| Mirum Pharmaceuticals, Inc. EC | $20.9M | 2.02% |
| Ptc Therapeutics, Inc. EC | $20.8M | 2.01% |
| Astrazeneca PLC EC | $19.2M | 1.85% |
| Neurocrine Biosciences, Inc. EC | $17.8M | 1.72% |
| Bridgebio Pharma, Inc. EC | $17.1M | 1.66% |
| Alnylam Pharmaceuticals, Inc. EC | $16.8M | 1.62% |
| Abivax Sa EC | $16.6M | 1.60% |
| Spyre Therapeutics, Inc. EC | $16.4M | 1.58% |
| Ionis Pharmaceuticals, Inc. EC | $15.4M | 1.48% |
| Oruka Therapeutics, Inc. EC | $15.2M | 1.47% |
| Mineralys Therapeutics, Inc. EC | $15.1M | 1.46% |
| Eyepoint, Inc. EC | $14.8M | 1.43% |
| Eli Lilly & Co. EC | $13.2M | 1.27% |
| Cg Oncology, Inc. EC | $12.6M | 1.21% |
| Indivior Pharmaceuticals, Inc. EC | $12.2M | 1.18% |
| Benitec Biopharma, Inc. EC | $12M | 1.16% |
| Arcutis Biotherapeutics, Inc. EC | $11.7M | 1.13% |
| Syndax Pharmaceuticals, Inc. EC | $10.6M | 1.02% |
| Amylyx Pharmaceuticals, Inc. EC | $10.4M | 1.00% |
| Cytokinetics, Inc. EC | $10.3M | 0.99% |
| Beone Medicines Ltd. EC | $9.87M | 0.95% |
| Tango Therapeutics, Inc. EC | $9.68M | 0.93% |
| Dyne Therapeutics, Inc. EC | $9.11M | 0.88% |
| Solid Biosciences, Inc. EC | $9.1M | 0.88% |
| Bicara Therapeutics, Inc. EC | $8.36M | 0.81% |
| Vaxcyte, Inc. EC | $8.34M | 0.80% |
| Alkermes PLC EC | $7.85M | 0.76% |
| Spyre Therapeutics, Inc. EC | $7.71M | 0.74% |
| Biontech Se EC | $7.59M | 0.73% |
| Nuvalent, Inc. EC | $7.57M | 0.73% |
| Xenon Pharmaceuticals, Inc. EC | $6.94M | 0.67% |
| Achieve Life Sciences, Inc. EC | $6.92M | 0.67% |
| Apogee Therapeutics, Inc. EC | $6.86M | 0.66% |
| Oric Pharmaceuticals, Inc. EC | $6.51M | 0.63% |
| Oruka Therapeutics, Inc. EC | $6.43M | 0.62% |
| Alto Neuroscience, Inc. EC | $6.16M | 0.59% |
| Olema Pharmaceuticals, Inc. EC | $5.47M | 0.53% |
| Phathom Pharmaceuticals, Inc. EC | $5.45M | 0.53% |
| Aura Biosciences, Inc. EC | $5.4M | 0.52% |
| Newamsterdam Pharma Co. Nv EC | $5.36M | 0.52% |
| Veradermics, Inc. EC | $5.34M | 0.52% |
| Inventiva Saca EC | $4.97M | 0.48% |
| Contineum Therapeutics, Inc. EC | $4.89M | 0.47% |
| Palisade Bio, Inc. EC | $4.24M | 0.41% |
| Alto Neuroscience, Inc. EC | $4.24M | 0.41% |
| Structure Therapeutics, Inc. EC | $4.22M | 0.41% |
Showing top 60 of 113 holdings.
Loading...
